Trial Profile
A Phase II, Open Label, Multicenter Study of Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Patients With EGFR Mutant Non-small Cell Lung Cancer Who Have Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BRILLIANT
- 09 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
- 20 Sep 2016 Status changed from not yet recruiting to recruiting.
- 28 Jan 2016 New trial record